Considering comorbidity in managing rheumatic diseases: Going where trials cannot go

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Aletaha, Daniel ^a   Dörner, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

CLINICAL PRACTICE; COMORBIDITY; EDITORIAL; HUMAN; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; RHEUMATOID ARTHRITIS; RISK FACTOR; NEOPLASM; NOTE; RHEUMATIC DISEASE;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; RHEUMATIC DISEASES;

EID: 79959733108     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3354     Document Type: Editorial

References (4)

1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874. 10.1016/S0140-6736(07)60784-3, 17570481.
2. Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, Symmons DP. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009, 68:1240-1246. 10.1136/ard.2008.091926, 18647854.
3. Boers M. A call for pragmatic treatment trials in rheumatoid arthritis. Nat Clin Pract Rheumatol 2008, 4:292-293. 10.1038/ncprheum0811, 18446137.
4. Elandt K, Aletaha D. Treating rheumatic patients with a malignancy. Arthritis Res Ther 2011, 13:223.